# Miguel A. Piris

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/401662/miguel-a-piris-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 403<br/>papers
 23,474<br/>citations
 74<br/>h-index
 139<br/>g-index

 431<br/>ext. papers
 26,520<br/>ext. citations
 5.8<br/>avg, IF
 5.89<br/>L-index

#	Paper	IF	Citations
403	International network of cancer genome projects. <i>Nature</i> , <b>2010</b> , 464, 993-8	50.4	1613
402	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. <i>Nature Genetics</i> , <b>2005</b> , 37, 391-400	36.3	1492
401	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , <b>2011</b> , 475, 101-5	50.4	1206
400	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5494-502	12.9	507
399	Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. <i>Histopathology</i> , <b>2002</b> , 41, 1-29	7.3	488
398	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , <b>2013</b> , 121, 4021-31;	2.2	473
397	quiz 4250 Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. <i>Nature Genetics</i> , <b>2014</b> , 46, 166-70	36.3	413
396	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. <i>British Journal of Haematology</i> , <b>2004</b> , 127, 173-83	4.5	413
395	Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. <i>Cancer Research</i> , <b>2010</b> , 70, 1408-18	10.1	373
394	Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 1467-73	12.9	360
393	Cell cycle deregulation in B-cell lymphomas. <i>Blood</i> , <b>2003</b> , 101, 1220-35	2.2	288
392	Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. <i>Cancer Cell</i> , <b>2015</b> , 27, 516-32	24.3	283
391	Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. <i>Cancer</i> , <b>1998</b> , 82, 567-75	6.4	254
390	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> ,	10.7	251
389	2012, 26, 2103-13  A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. <i>Cancer Research</i> , 2007, 67, 3450-60	10.1	246
388	The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. <i>Cancer Cell</i> , <b>2006</b> , 9, 301-12	24.3	245
387	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , <b>2012</b> , 120, 3986-96	2.2	223

#### (1999-2003)

386	Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. <i>Blood</i> , <b>2003</b> , 101, 681-9	2.2	208	
385	Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 193-203	5.8	207	
384	Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. <i>Leukemia</i> , <b>2008</b> , 22, 487-95	10.7	205	
383	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. <i>Genome Research</i> , <b>2009</b> , 19, 438-51	9.7	201	
382	Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 81-90	6.7	186	
381	Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. <i>Blood</i> , <b>2005</b> , 105, 4445-54	2.2	165	
380	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , <b>2013</b> , 121, 2715-24	2.2	157	
379	p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. <i>British Journal of Cancer</i> , <b>1994</b> , 69, 337-41	8.7	157	
378	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , <b>2013</b> , 122, 2673-82	2.2	154	
377	PLCG1 mutations in cutaneous T-cell lymphomas. <i>Blood</i> , <b>2014</b> , 123, 2034-43	2.2	150	
376	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. <i>Blood</i> , <b>2002</b> , 100, 1648-1654	2.2	147	
375	Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. <i>Cancer Cell</i> , <b>2009</b> , 16, 103-14	24.3	146	
374	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , <b>2011</b> , 117, 1595-604	2.2	145	
373	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. <i>Blood</i> , <b>2010</b> , 116, 1479-88	2.2	145	
372	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. <i>Modern Pathology</i> , <b>2012</b> , 25, 968-82	9.8	140	
371	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , <b>2008</b> , 112, 3088-98	2.2	138	
370	Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. <i>Blood</i> , <b>2002</b> , 99, 1299-304	2.2	138	
369	7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. <i>American Journal of Pathology</i> , <b>1999</b> , 154, 1583-9	5.8	128	

368	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , <b>2013</b> , 98, 255-63	6.6	125
367	Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. <i>Haematologica</i> , <b>2007</b> , 92, 1059-66	6.6	125
366	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. <i>Blood</i> , <b>2005</b> , 106, 1831-8	2.2	123
365	The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. <i>Cancer Research</i> , <b>2003</b> , 63, 8226-32	10.1	120
364	Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. <i>Blood</i> , <b>2003</b> , 102, 1042-50	2.2	118
363	FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. <i>Leukemia</i> , <b>2005</b> , 19, 2247-5	5 <b>3</b> 10.7	118
362	Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. <i>Journal of Pathology</i> , <b>2005</b> , 206, 123-34	9.4	117
361	Targeting the T cell receptor Ethain constant region for immunotherapy of T cell malignancies.  Nature Medicine, 2017, 23, 1416-1423	50.5	112
360	Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. <i>American Journal of Surgical Pathology</i> , <b>2001</b> , 25, 1268-76	6.7	111
359	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. <i>Leukemia</i> , <b>2014</b> , 28, 823-9	10.7	110
358	Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. <i>Blood</i> , <b>2006</b> , 108, 662-8	2.2	110
357	Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3940-7	2.2	110
356	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. <i>Blood</i> , <b>2003</b> , 101, 4042-6	2.2	109
355	Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. <i>Cancer Research</i> , <b>2006</b> , 66, 5744-56	10.1	108
354	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. <i>Haematologica</i> , <b>2010</b> , 95, 1342-9	6.6	106
353	Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. <i>American Journal of Pathology</i> , <b>1998</b> , 153, 887-97	5.8	103
352	Peripheral T-cell lymphoma with follicular T-cell markers. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 1787-99	6.7	102
351	TCR-lexpression in primary cutaneous T-cell lymphomas. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 375-84	6.7	100

# (2006-2008)

350	PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. <i>American Journal of Surgical Pathology</i> , <b>2008</b> , 32, 1252-7	6.7	100
349	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , <b>2014</b> , 27, 958-71	9.8	99
348	Anomalous High p27/KIP1 Expression in a Subset of Aggressive B-Cell Lymphomas Is Associated With Cyclin D3 Overexpression. p27/KIP1@yclin D3 Colocalization in Tumor Cells. <i>Blood</i> , <b>1999</b> , 94, 765-7	7 <mark>2</mark> 2	98
347	Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. <i>Leukemia</i> , <b>2012</b> , 26, 1638-46	10.7	97
346	Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2338-49	12.9	96
345	Cancer induction by restriction of oncogene expression to the stem cell compartment. <i>EMBO Journal</i> , <b>2009</b> , 28, 8-20	13	96
344	miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. <i>Cell Cycle</i> , <b>2010</b> , 9, 3277-85	4.7	92
343	EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from peru in children and young adults. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 1773-82	6.7	91
342	Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. <i>American Journal of Surgical Pathology</i> , <b>2003</b> , 27, 762-71	6.7	91
341	Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1825-37	5.8	91
340	Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. <i>Leukemia</i> , <b>2014</b> , 28, 1334-40	10.7	90
339	P53 protein expression in lymphomas and reactive lymphoid tissue. <i>Journal of Pathology</i> , <b>1992</b> , 166, 23	5944	90
338	Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. <i>Leukemia</i> , <b>2006</b> , 20, 1047-54	10.7	86
337	The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. <i>Haematologica</i> , <b>2010</b> , 95, 432-9	6.6	84
336	Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. <i>Haematologica</i> , <b>2010</b> , 95, 613-	2 <sup>6.6</sup>	83
335	Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2002</b> , 10, 7-14	1.9	83
334	Large B-cell lymphoma with Hodgkin's features. <i>Histopathology</i> , <b>2005</b> , 47, 101-10	7-3	81
333	Evolving concepts in the pathogenesis of hairy-cell leukaemia. <i>Nature Reviews Cancer</i> , <b>2006</b> , 6, 437-48	31.3	79

332	p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. <i>American Journal of Pathology</i> , <b>2000</b> , 156, 1565-72	5.8	77
331	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , <b>2013</b> , 122, 2683-93	2.2	75
330	Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. <i>Modern Pathology</i> , <b>2006</b> , 19, 684-94	9.8	75
329	Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. <i>American Journal of Pathology</i> , <b>2001</b> , 158, 1843-50	5.8	74
328	Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. <i>Blood</i> , <b>2012</b> , 119, e9-e21	2.2	73
327	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. <i>Blood</i> , <b>2011</b> , 118, 1034-40	2.2	73
326	Building an outcome predictor model for diffuse large B-cell lymphoma. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 613-22	5.8	72
325	Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. <i>Leukemia</i> , <b>2003</b> , 17, 2016-24	10.7	70
324	The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. <i>Haematologica</i> , <b>2006</b> , 91, 1605-12	6.6	70
323	MicroRNA signatures in B-cell lymphomas. <i>Blood Cancer Journal</i> , <b>2012</b> , 2, e57	7	68
322	Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica, <b>2008</b> , 93, 670-9	6.6	68
321	Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. <i>Histopathology</i> , <b>2006</b> , 48, 481-504	7.3	68
320	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2016</b> , 7, 2401-16	3.3	68
319	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 764-769	11.5	67
318	Cutaneous follicular B-cell lymphoma: description of a series of 18 cases. <i>American Journal of Surgical Pathology</i> , <b>2001</b> , 25, 875-83	6.7	67
317	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , <b>2016</b> , 127, 221-32	2.2	65
316	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. <i>Haematologica</i> , <b>2006</b> , 91, 467-74	6.6	65
315	Mantle cell lymphoma: transcriptional regulation by microRNAs. <i>Leukemia</i> , <b>2010</b> , 24, 1335-42	10.7	64

# (2004-2001)

314	Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. <i>American Journal of Pathology</i> , <b>2001</b> , 159, 205-13	5.8	64
313	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. <i>Blood</i> , <b>2011</b> , 118, 5517-27	2.2	63
312	Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. <i>Blood</i> , <b>2008</b> , 111, 351-8	2.2	63
311	Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. <i>British Journal of Haematology</i> , <b>2012</b> , 159, 164-71	4.5	62
310	MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 644-51	6.7	60
309	The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. <i>Blood</i> , <b>2012</b> , 120, 1782-90	2.2	60
308	Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers. <i>Modern Pathology</i> , <b>2009</b> , 22, 1006-15	9.8	60
307	Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. <i>Haematologica</i> , <b>2010</b> , 95, 1122-9	6.6	59
306	Lymphoma microenvironment: culprit or innocent?. <i>Leukemia</i> , <b>2008</b> , 22, 49-58	10.7	58
305	Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas. <i>Modern Pathology</i> , <b>2002</b> , 15, 211-20	9.8	58
304	Intrafollicular neoplasia/in situ follicular lymphoma: review of a series of 13 cases. <i>Histopathology</i> , <b>2010</b> , 56, 658-62	7.3	57
303	A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma. <i>Histopathology</i> , <b>1998</b> , 33, 230-9	7.3	57
302	Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. <i>Blood</i> , <b>2011</b> , 117, 6255-66	5 2.2	56
301	Genome wide DNA-profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 245-55	4.5	56
300	Identification of MNDA as a new marker for nodal marginal zone lymphoma. <i>Leukemia</i> , <b>2009</b> , 23, 1847-5	<b>7</b> 10.7	56
299	Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors. <i>Journal of Pathology</i> , <b>2004</b> , 204, 528-37	9.4	56
298	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 197-206	4.3	55
297	Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. <i>Blood</i> , <b>2004</b> , 103, 2351-7	2.2	55

296	Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , <b>2015</b> , 6, 5615-33	3.3	54
295	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 5597-614	3.3	53
294	Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1664-73	2.2	53
293	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 644-657	12.5	52
292	Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5113-23	12.9	52
291	Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone B-cell lymphoma. <i>British Journal of Haematology</i> , <b>1997</b> , 98, 446-9	4.5	52
290	Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma?. <i>Histopathology</i> , <b>2002</b> , 40, 22-30	7.3	52
289	Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. <i>Modern Pathology</i> , <b>2009</b> , 22, 753-61	9.8	51
288	Polycomb proteins in hematologic malignancies. <i>Blood</i> , <b>2010</b> , 116, 5465-75	2.2	51
287	Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. <i>Haematologica</i> , <b>2012</b> , 97, 1080-4	6.6	50
286	miR-217 is an oncogene that enhances the germinal center reaction. <i>Blood</i> , <b>2014</b> , 124, 229-39	2.2	49
285	Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 814-23	6.1	49
284	Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma. <i>Leukemia</i> , <b>2014</b> , 28, 1103-12	10.7	48
283	T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. <i>Histopathology</i> , <b>2002</b> , 41, 216-29	7.3	48
282	Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. <i>Leukemia</i> , <b>2007</b> , 21, 1984-91	10.7	47
281	Aberrant Bcl6 protein expression in mantle cell lymphoma. <i>American Journal of Surgical Pathology</i> , <b>2004</b> , 28, 1051-6	6.7	47
280	p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. <i>Blood</i> , <b>2002</b> , 99, 1411-8	2.2	47
279	NIK controls classical and alternative NF- <b>B</b> activation and is necessary for the survival of human T-cell lymphoma cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2319-30	12.9	46

278	Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. <i>Journal of Pathology</i> , <b>1993</b> , 169, 405-12	9.4	46	
277	The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. <i>Blood</i> , <b>2014</b> , 123, 2893-4	2.2	45	
276	Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. <i>Modern Pathology</i> , <b>2017</b> , 30, 85-94	9.8	45	
275	Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 569-77	4.5	45	
274	Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 221-31	4.5	45	
273	Nodal and splenic marginal zone B cell lymphomas. <i>Hematological Oncology</i> , <b>2005</b> , 23, 108-18	1.3	45	
272	p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides. <i>Laboratory Investigation</i> , <b>2002</b> , 82, 123-32	5.9	44	
271	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. <i>Haematologica</i> , <b>2014</b> , 99, 222-31	6.6	43	
270	A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 12461-6	11.5	43	
269	A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas. <i>American Journal of Pathology</i> , <b>2002</b> , 160, 1371-80	5.8	43	
268	Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 188-98	4.5	42	
267	The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma. <i>Infectious Agents and Cancer</i> , <b>2014</b> , 9, 12	3.5	42	
266	Crystal-storing histiocytosis and immunocytoma associated with multifocal fibrosclerosis. <i>Histopathology</i> , <b>1998</b> , 33, 459-64	7.3	42	
265	Composite Hodgkin lymphoma and mantle cell lymphoma: two clonally unrelated tumors. <i>American Journal of Surgical Pathology</i> , <b>2003</b> , 27, 1577-80	6.7	42	
264	. Applied Immunohistochemistry & Molecular Morphology, <b>2002</b> , 10, 7-14		42	
263	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. <i>Leukemia</i> , <b>2016</b> , 30, 361-72	10.7	41	
262	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , <b>2013</b> , 122, 2630-40	2.2	41	
261	Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 185-94	1.9	41	

260	Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant?. <i>Human Pathology</i> , <b>1999</b> , 30, 1153-60	3.7	41
259	Detection of the bcl-1 rearrangement at the major translocation cluster in frozen and paraffin-embedded tissues of mantle cell lymphomas by polymerase chain reaction. <i>American Journal of Clinical Pathology</i> , <b>1996</b> , 105, 532-7	1.9	41
258	Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features. <i>American Journal of Surgical Pathology</i> , <b>1997</b> , 21, 772-80	6.7	41
257	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2016</b> , 128, 3083-3100	2.2	41
256	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , <b>2015</b> , 28, 1555-73	9.8	40
255	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , <b>2015</b> , 125, 1922-31	2.2	40
254	Persistent and generalized lymphadenopathy: a lesion of follicular dendritic cells? An immunohistologic and ultrastructural study. <i>American Journal of Clinical Pathology</i> , <b>1987</b> , 87, 716-24	1.9	40
253	SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. <i>Blood</i> , <b>2013</b> , 121, 643-7	2.2	39
252	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. <i>Blood</i> , <b>2010</b> , 116, e12-7	2.2	39
251	MicroRNA losses in the frequently deleted region of 7q in SMZL. <i>Leukemia</i> , <b>2007</b> , 21, 2547-9	10.7	39
250	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3593-605	12.9	39
249	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. <i>Leukemia</i> , <b>2017</b> , 31, 625-636	10.7	38
248	TCL1A expression delineates biological and clinical variability in B-cell lymphoma. <i>Modern Pathology</i> , <b>2009</b> , 22, 206-15	9.8	38
247	Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. <i>Haematologica</i> , <b>2015</b> , 100, e450-3	6.6	38
246	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. <i>Blood</i> , <b>2002</b> , 100, 1648-54	2.2	38
245	Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. <i>Leukemia</i> , <b>2012</b> , 26, 180-3	10.7	37
244	p27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas and is associated with an adverse clinical outcome. <i>British Journal of Cancer</i> , <b>1999</b> , 80, 1427-34	8.7	37
243	Value of PCR detection of TCR gamma gene rearrangement in the diagnosis of cutaneous lymphocytic infiltrates. <i>Diagnostic Molecular Pathology</i> , <b>1994</b> , 3, 275-82		37

# (2001-2012)

242	New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing. <i>PLoS ONE</i> , <b>2012</b> , 7, e38158	3.7	37
241	True histiocytic lymphoma of the stomach associated with low-grade B-cell mucosa-associated lymphoid tissue (MALT)-type lymphoma. <i>American Journal of Surgical Pathology</i> , <b>1996</b> , 20, 1406-11	6.7	37
240	Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 930-42	5.8	36
239	Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features. <i>Histopathology</i> , <b>2015</b> , 66, 846-55	7.3	35
238	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , <b>2013</b> , 121, 4529-40	2.2	35
237	Splenic follicular lymphoma: clinicopathologic characteristics of a series of 32 cases. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 730-8	6.7	35
236	Large B-cell lymphoma presenting in the spleen: identification of different clinicopathologic conditions. <i>American Journal of Surgical Pathology</i> , <b>2003</b> , 27, 895-902	6.7	35
235	Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6796-806	12.9	35
234	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 1700-1716	5.8	34
233	Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. <i>Blood</i> , <b>2012</b> , 120, 812-21	2.2	34
232	High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 712-2	2 <b>€</b> ·5	34
231	Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , <b>2010</b> , 28, 62-7	1.3	34
230	Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. <i>Clinical and Experimental Metastasis</i> , <b>1989</b> , 7, 213-26	4.7	34
229	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. <i>Blood</i> , <b>2013</b> , 122, 2233-41	2.2	33
228	A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1367-75	12.9	33
227	Light-chain-restricted germinal centres in reactive lymphadenitis: report of eight cases.  Histopathology, <b>2008</b> , 52, 436-44	7.3	33
226	Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 95-101	1.9	33
225	Primary cutaneous large B-cell lymphoma: the relation between morphology, clinical presentation, immunohistochemical markers, and survival. <i>American Journal of Surgical Pathology</i> , <b>2001</b> , 25, 307-15	6.7	33

224	MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. <i>Journal of Pathology</i> , <b>1995</b> , 177, 27-34	9.4	33
223	Monocytoid B Cells. <i>American Journal of Surgical Pathology</i> , <b>1994</b> , 18, 1131-1139	6.7	33
222	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , <b>2015</b> , 29, 1390-401	10.7	32
221	MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 336-47	4.5	32
220	Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 929-31	1.9	32
219	E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. <i>Cancer Research</i> , <b>2009</b> , 69, 4052-8	10.1	32
218	The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. <i>Leukemia</i> , <b>2008</b> , 22, 1268-72	10.7	32
217	Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. <i>Journal of Cellular Biochemistry</i> , <b>2007</b> , 100, 339-48	4.7	32
216	BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas. <i>Journal of Pathology</i> , <b>2008</b> , 214, 498-507	9.4	32
215	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 23157-80	3.3	32
214	Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. <i>Blood</i> , <b>2017</b> , 129, 1042-1045	2.2	31
213	Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. <i>Modern Pathology</i> , <b>2013</b> , 26, 889-901	9.8	31
212	Overexpression of human DNA polymerase mu (Pol mu) in a Burkitt's lymphoma cell line affects the somatic hypermutation rate. <i>Nucleic Acids Research</i> , <b>2004</b> , 32, 5861-73	20.1	31
211	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , <b>2018</b> , 20, 574-593	6.4	30
210	Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. <i>Genomics</i> , <b>2006</b> , 87, 113-8	4.3	30
209	Epstein-Barr virus-latent membrane protein 1 expression has a favorable influence in the outcome of patients with Hodgkin's Disease treated with chemotherapy. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 39, 563	-72	30
208	Other cancers in patients with gastric MALT lymphoma. <i>Leukemia and Lymphoma</i> , <b>1999</b> , 33, 161-8	1.9	30
207	The detection of B-cell monoclonal populations by polymerase chain reaction: accuracy of approach and application in gastric endoscopic biopsy specimens. <i>Human Pathology</i> , <b>1993</b> , 24, 1184-8	3.7	30

# (2013-2009)

206	Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. <i>Cancer</i> , <b>2009</b> , 115, 3728-37	6.4	29
205	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphomais it necessary?. <i>Oncotarget</i> , <b>2015</b> , 6, 13933-45	3.3	29
204	Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. <i>Haematologica</i> , <b>2015</b> , 100, e25-7	6.6	28
203	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , <b>2014</b> , 120, 1818-29	6.4	28
202	Proliferation centers in chronic lymphocytic leukemia: the niche where NF-kappaB activation takes place. <i>Leukemia</i> , <b>2010</b> , 24, 872-6	10.7	28
201	Gastric B-cell mucosa associated lymphoid tissue lymphoma: a clinicopathological study in 56 patients. <i>Gut</i> , <b>1992</b> , 33, 1307-11	19.2	28
200	Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. <i>Modern Pathology</i> , <b>2006</b> , 19, 1055-67	9.8	27
199	NFB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. <i>Modern Pathology</i> , <b>2014</b> , 27, 1331-7	9.8	26
198	Unique phenotypic profile of monocytoid B cells: differences in comparison with the phenotypic profile observed in marginal zone B cells and so-called monocytoid B cell lymphoma. <i>American Journal of Pathology</i> , <b>2001</b> , 158, 1363-9	5.8	26
197	Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. <i>Pathology</i> , <b>2020</b> , 52, 154-165	1.6	26
196	The Spectrum of EBV-Positive Mucocutaneous Ulcer: A Study of 9 Cases. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 201-210	6.7	25
195	Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. <i>Haematologica</i> , <b>2013</b> , 98, 57-64	6.6	25
194	CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified. <i>American Journal of Surgical Pathology</i> , <b>2016</b> , 40, 378-85	6.7	25
193	Incidental and Isolated Follicular Lymphoma In Situ and Mantle Cell Lymphoma In Situ Lack Clinical Significance. <i>American Journal of Surgical Pathology</i> , <b>2016</b> , 40, 943-9	6.7	25
192	Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. <i>Histopathology</i> , <b>2005</b> , 46, 241-55	7.3	24
191	CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. <i>Haematologica</i> , <b>2019</b> , 104, 226-235	6.6	24
190	Splenic marginal zone lymphoma. Best Practice and Research in Clinical Haematology, 2017, 30, 56-64	4.2	23
189	Down-regulation of specific miRNAs enhances the expression of the gene Smoothened and contributes to T-cell lymphoblastic lymphoma development. <i>Carcinogenesis</i> , <b>2013</b> , 34, 902-8	4.6	23

188	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , <b>2011</b> , 29, 38-41	1.3	23
187	Expression pattern of XBP1(S) in human B-cell lymphomas. <i>Haematologica</i> , <b>2009</b> , 94, 419-22	6.6	23
186	Cutaneous presentation of follicular lymphomas. <i>Modern Pathology</i> , <b>2001</b> , 14, 913-9	9.8	23
185	Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. <i>Oncotarget</i> , <b>2018</b> , 9, 16124-16133	3.3	23
184	Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. <i>Leukemia</i> , <b>2016</b> , 30, 94-103	10.7	22
183	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , <b>2018</b> , 32, 353-363	10.7	22
182	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0125203	3.7	22
181	Epstein-Barr virus-positive systemic NK/T-cell lymphomas in children: report of six cases. <i>Histopathology</i> , <b>2011</b> , 59, 1183-93	7.3	21
180	KSHV- and EBV-associated germinotropic lymphoproliferative disorder: a rare lymphoproliferative disease of HIV patient with plasmablastic morphology, indolent course and favourable response to therapy. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 1444-7	1.9	21
179	p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation?. <i>Leukemia and Lymphoma</i> , <b>1995</b> , 17, 35-42	1.9	21
178	MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. <i>Journal of Pathology</i> , <b>1996</b> , 180, 58-64	9.4	21
177	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , <b>2019</b> ,	9.8	20
176	Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas. <i>PLoS ONE</i> , <b>2011</b> , 6, e24939	3.7	20
175	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. <i>Haematologica</i> , <b>2010</b> , 95, 2056-62	6.6	20
174	Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. <i>Oncogene</i> , <b>2006</b> , 25, 2565-74	9.2	20
173	RelA NF- <b>B</b> subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , <b>2016</b> , 8, 3321-3340	5.6	20
172	Clinical and diagnostic relevance of -and -mutations in splenic marginal zone lymphoma. <i>Haematologica</i> , <b>2017</b> , 102, e310-e312	6.6	19
171	Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study. <i>Modern Pathology</i> , <b>2014</b> , 27, 281-93	9.8	19

170	NF- <b>B</b> directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, 11025-39	20.1	19
169	Transcriptional response of T cells to IFN-alpha: changes induced in IFN-alpha-sensitive and resistant cutaneous T cell lymphoma. <i>Journal of Interferon and Cytokine Research</i> , <b>2004</b> , 24, 185-95	3.5	19
168	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. <i>Oncotarget</i> , <b>2016</b> , 7, 1803	6 <sup>-3</sup> 4 <sup>3</sup> 9	19
167	C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. <i>Haematologica</i> , <b>2016</b> , 101, e336-8	6.6	19
166	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , <b>2015</b> , 28, 1297-314	9.8	18
165	Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor- <b>B</b> and nuclear factor of activated T cells pathways. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 147-155	4	17
164	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , <b>2012</b> , 23, 729-735	10.3	17
163	Splenic Marginal Zone Lymphoma. <i>Advances in Anatomic Pathology</i> , <b>1997</b> , 4, 191-201	5.1	17
162	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , <b>2016</b> , 8, 345-65	5.6	17
161	High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. <i>Oncotarget</i> , <b>2014</b> , 5, 4694-708	3.3	17
160	PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases. <i>PLoS ONE</i> , <b>2014</b> , 9, e112148	3.7	16
159	Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. <i>Blood Cancer Journal</i> , <b>2013</b> , 3, e111	7	16
158	Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways. <i>Blood</i> , <b>2008</b> , 111, 1665-76	2.2	16
157	Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma. <i>Laboratory Investigation</i> , <b>2003</b> , 83, 143-52	5.9	16
156	Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts. <i>American Journal of Pathology</i> , <b>2002</b> , 160, 569-78	5.8	16
155	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. <i>Oncotarget</i> , <b>2017</b> , 8, 111386-111395	3.3	16
154	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , <b>2019</b> , 14, e0212813	3.7	15
153	Evaluation of NF- <b>B</b> subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , <b>2015</b> , 28, 1202-13	9.8	15

152	Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , <b>2018</b> , 245, 61-73	9.4	15
151	An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2032-40	12.9	15
150	Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. <i>Haematologica</i> , <b>2015</b> , 100, 1460-8	6.6	15
149	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. <i>Modern Pathology</i> , <b>2013</b> , 26, 171-81	9.8	15
148	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 435-9	4.5	15
147	Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. British Journal of Dermatology, <b>2009</b> , 160, 92-102	4	15
146	E2F4 plays a key role in Burkitt lymphoma tumorigenesis. <i>Leukemia</i> , <b>2012</b> , 26, 2277-85	10.7	15
145	Transcriptomal profiling of the cellular response to DNA damage mediated by Slug (Snai2). <i>British Journal of Cancer</i> , <b>2008</b> , 98, 480-8	8.7	15
144	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 956-61	3.9	14
143	Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. <i>Journal of Pathology</i> , <b>2019</b> , 247, 416-421	9.4	14
142	Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 411-21	3.5	13
141	Marginal zone lymphoma. <i>Seminars in Diagnostic Pathology</i> , <b>2011</b> , 28, 135-45	4.3	13
140	Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 812-9	1.9	13
139	Evaluation of the international index in the prognosis of high grade gastric malt lymphoma. <i>Leukemia and Lymphoma</i> , <b>1996</b> , 24, 159-63	1.9	13
138	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies <b>2019</b> , 7, 272		12
137	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 148	22.4	12
136	Castleman Disease and Rosai-Dorfman Disease. Seminars in Diagnostic Pathology, <b>2018</b> , 35, 44-53	4.3	12
135	Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.  Haematologica, 2015, 100, e200-3	6.6	12

134	FAS system deregulation in T-cell lymphoblastic lymphoma. Cell Death and Disease, 2014, 5, e1110	9.8	12
133	Primary mediastinal B-cell lymphoma: treatment and therapeutic targets. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1050-61	1.9	12
132	An A91V SNP in the perforin gene is frequently found in NK/T-cell lymphomas. <i>PLoS ONE</i> , <b>2014</b> , 9, e915	<b>23</b> .7	12
131	Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 49	7	11
130	Mutational profile of primary breast diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2017</b> , 8, 102888-10289	73.3	11
129	and activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. <i>Haematologica</i> , <b>2018</b> , 103, e537-e540	6.6	11
128	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 499-503	4.5	11
127	Somatic hypermutation signature in B-cell low-grade lymphomas. <i>Haematologica</i> , <b>2008</b> , 93, 1186-94	6.6	11
126	Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis. <i>Leukemia</i> , <b>2018</b> , 32, 1822-18	826 <sup>.7</sup>	10
125	Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 183, 497-501	4.5	10
124	Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. <i>Medicina Clīpica</i> , <b>2018</b> , 151, 362-367	1	10
123	Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. <i>Haematologica</i> , <b>2012</b> , 97, 1614-6	6.6	10
122	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma: A Potential Diagnostic Pitfall. <i>American Journal of Surgical Pathology</i> , <b>2020</b> , 44, 657-664	6.7	10
121	-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers. <i>Haematologica</i> , <b>2019</b> , 104, e158-e162	6.6	10
120	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1685-1688	8.7	9
119	HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 580-1	4.5	9
118	Adult pityriasis lichenoides-like mycosis fungoides: a clinical variant of mycosis fungoides. <i>International Journal of Dermatology</i> , <b>2014</b> , 53, 1331-8	1.7	9
117	HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 352-6	4.5	9

116	Early phase of Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma of the elderly mimicking EBV-positive reactive follicular hyperplasia. <i>Histopathology</i> , <b>2011</b> , 59, 571-5	7.3	9
115	Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 1699-708	1.9	9
114	Kaposi's sarcoma in a patient with temporal arteritis treated with corticosteroid. <i>Journal of the American Academy of Dermatology</i> , <b>1991</b> , 24, 1027-8	4.5	9
113	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 249-260	6.6	9
112	Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis: Analysis of Histology and Lymphoid Subpopulations. <i>American Journal of Clinical Pathology</i> , <b>2018</b> , 150, 310-317	1.9	8
111	IgV(H) and bcl6 somatic mutation analysis reveals the heterogeneity of cutaneous B-cell lymphoma, and indicates the presence of undisclosed local antigens. <i>Modern Pathology</i> , <b>2004</b> , 17, 623-30	9.8	8
110	Ultrastructure of 26 cases of Ki-1 lymphomas: morphoimmunologic correlation. <i>Ultrastructural Pathology</i> , <b>1990</b> , 14, 381-97	1.3	8
109	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. <i>Oncotarget</i> , <b>2018</b> , 9, 30869-30882	3.3	8
108	Breast implant-associated Epstein-Barr virus-positive large B-cell lymphomas: a report of three cases. <i>Haematologica</i> , <b>2020</b> , 105, e412-e414	6.6	7
107	Mycosis fungoides progression could be regulated by microRNAs. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198477	3.7	7
106	Colorectal adenomas contain multiple somatic mutations that do not coincide with synchronous adenocarcinoma specimens. <i>PLoS ONE</i> , <b>2015</b> , 10, e0119946	3.7	7
105	Follicular T-cell lymphoma: description of a case with characteristic findings suggesting it is a different condition from AITL. <i>Histopathology</i> , <b>2009</b> , 54, 902-4	7.3	7
104	Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 571-81	1.9	7
103	Thymoma and progressive T-cell lymphocytosis. <i>Annals of Oncology</i> , <b>2007</b> , 18, 603-4	10.3	7
102	Primary cutaneous follicular helper T-cell lymphoma. <i>Journal of Cutaneous Pathology</i> , <b>2016</b> , 43, 164-70	1.7	7
101	Large Cells With CD30 Expression and Hodgkin-like Features in Primary Cutaneous Marginal Zone B-Cell Lymphoma: A Study of 13 Cases. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1191-1202	6.7	7
100	Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 34	7	6
99	Angioimmunoblastic T-cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression. <i>Journal of Cutaneous Pathology</i> , <b>2016</b> , 43, 1203-1210	1.7	6

# (2015-2021)

98	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. <i>Scientific Reports</i> , <b>2021</b> , 11, 1886	4.9	6
97	Mutual regulation between BCL6 and a specific set of miRNAs controls T phenotype in peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 587-590	4.5	5
96	BCL7A protein expression in normal and malignant lymphoid tissues. <i>British Journal of Haematology</i> , <b>2013</b> , 160, 106-9	4.5	5
95	Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. <i>Modern Pathology</i> , <b>2011</b> , 24, 698-707	9.8	5
94	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , <b>2021</b> ,	2.2	5
93	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , <b>2020</b> , 4, 3391-3404	7.8	5
92	Peripheral T-cell lymphoma: Molecular profiling recognizes subclasses and identifies prognostic markers. <i>Blood Advances</i> , <b>2021</b> ,	7.8	5
91	Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia. <i>Scientific Reports</i> , <b>2019</b> , 9, 975	4.9	4
90	Cutaneous T-cell lymphoma: two faces of the same coin. <i>Journal of Investigative Dermatology</i> , <b>2010</b> , 130, 348-51	4.3	4
89	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. <i>Blood</i> , <b>2019</b> , 134, 468-468	2.2	4
88	Update on peripheral T-cell lymphomas with T-helper phenotype: 'Are there too many subtypes?. <i>Seminars in Diagnostic Pathology</i> , <b>2020</b> , 37, 24-31	4.3	4
87	The presence of Merkel cell carcinoma polyomavirus is associated with a distinct phenotype in neoplastic Merkel cell carcinoma cells and their tissue microenvironment. <i>PLoS ONE</i> , <b>2020</b> , 15, e023251	7 <sup>3.7</sup>	4
86	Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 134-42	1.9	3
85	Epstein-Barr virus-associated large B-cell lymphoma transformation in marginal zone B-cell lymphoma: a series of four cases. <i>Histopathology</i> , <b>2020</b> , 77, 112-122	7.3	3
84	High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229743	3.7	3
83	Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. <i>Scientific Reports</i> , <b>2020</b> , 10, 6721	4.9	3
82	I. Pathological and clinical diversity in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , <b>2013</b> , 31 Suppl 1, 23-5	1.3	3
81	CD 30-positive transformed follicular lymphoma: two case reports and literature review. <i>Histopathology</i> , <b>2015</b> , 67, 918-22	7.3	3

80	Localized lymphomatoid papulosis. International Journal of Dermatology, 2015, 54, e98-100	1.7	3
79	EBV-positive non-Hodgkin's lymphoma developing after phenytoin therapy. <i>British Journal of Haematology</i> , <b>1996</b> , 95, 376-9	4.5	3
78	Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines. <i>PLoS ONE</i> , <b>2017</b> , 12, e0177524	3.7	3
77	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. <i>Oncotarget</i> , <b>2015</b> , 6, 25452-65	3.3	3
76	Mycosis Fungoides and Sary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
75	Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?. <i>American Journal of Dermatopathology</i> , <b>2019</b> , 41, 846-850	0.9	3
74	p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 661-664	4.5	2
73	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , <b>2015</b> , 27, 744	24.3	2
72	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. <i>American Journal of Clinical Pathology</i> , <b>2019</b> , 152, 277-301	1.9	2
71	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , <b>2014</b> , 99, e138-41	6.6	2
70	Childhood florid follicular hyperplasia with immunoglobulin light-chain restriction in the gastrointestinal tract. <i>Histopathology</i> , <b>2014</b> , 65, 805-13	7.3	2
69	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. <i>Modern Pathology</i> , <b>2013</b> , 26, 617	9.8	2
68	Persistent polyclonal B-cell lymphocytosis with splenomegaly: histologic description of 2 cases. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1085-90	6.7	2
67	Hairy cell leukemia, blastic type: description of spleen morphology and immunophenotype of a distinctive case. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 1589-92	1.9	2
66	Posible implicacili de las alteraciones moleculares de la vil de TNF en la tumorigliesis de la micosis fungoide. Descripcili de un posible chip de diagnilico molecular en micosis fungoide. <i>Actas Dermo-sifiliogr</i> icas, <b>2004</b> , 95, 86-96	0.5	2
65	Lennert's lymphoma with giant multivesicular lysosomal bodies optically visible. <i>Ultrastructural Pathology</i> , <b>1992</b> , 16, 283-90	1.3	2
64	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , <b>2018</b> , 132, 922-9	2 <sup>2</sup> .2	2
63	Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells. <i>Blood</i> , <b>2010</b> , 116, 634-634	2.2	2

62	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , <b>2011</b> , 118, 949-949	2.2	2
61	Activating Mutations In Fyn Kinase In Peripheral T-Cell Lymphomas. <i>Blood</i> , <b>2013</b> , 122, 811-811	2.2	2
60	Unique Versus Common: Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations. <i>Blood</i> , <b>2015</b> , 126, 1479-14	1 <del>79</del> 2	2
59	Anomalous High p27/KIP1 Expression in a Subset of Aggressive B-Cell Lymphomas Is Associated With Cyclin D3 Overexpression. p27/KIP1ffyclin D3 Colocalization in Tumor Cells. <i>Blood</i> , <b>1999</b> , 94, 765-7	722	2
58	Genetic Characterization and Clinical Features of Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
57	Atypical Histiocytic Lesion Preceding a Peripheral T-Cell Lymphoma Involving the Skin Exhibiting the Same Molecular Alterations. <i>American Journal of Dermatopathology</i> , <b>2019</b> , 41, 148-154	0.9	2
56	Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 82-99	4.5	2
55	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncolmmunology</i> , <b>2021</b> , 10, 1928365	7.2	2
54	B-cell lymphoblastic lymphoma presenting as solitary temporal mass with amplification of AML1/RUNX1: case report. <i>Hematological Oncology</i> , <b>2017</b> , 35, 380-384	1.3	1
53	Cutaneous EBV-associated lymphoma?. <i>Blood</i> , <b>2013</b> , 122, 3095	2.2	1
53 52	Cutaneous EBV-associated lymphoma?. <i>Blood</i> , <b>2013</b> , 122, 3095  Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 25	2.2	1
	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and		
52	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 25  MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not	7	1
52 51	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 25  MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. <i>Blood</i> , <b>2019</b> , 134, 5092-5092  Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and	7 2.2 2.2	1
52 51 50	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 25  MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. <i>Blood</i> , <b>2019</b> , 134, 5092-5092  Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and Mouse Models of Mantle Cell Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 608-608  Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet	7 2.2 2.2	1 1
52 51 50 49	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 25  MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. <i>Blood</i> , <b>2019</b> , 134, 5092-5092  Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and Mouse Models of Mantle Cell Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 608-608  Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System. <i>Blood</i> , <b>2011</b> , 118, 1583-1583  Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and	7 2.2 2.2	1 1 1
52 51 50 49 48	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 25  MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. <i>Blood</i> , <b>2019</b> , 134, 5092-5092  Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and Mouse Models of Mantle Cell Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 608-608  Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System. <i>Blood</i> , <b>2011</b> , 118, 1583-1583  Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. <i>Blood</i> , <b>2021</b> , 138, 2395-2395  Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular	7 2.2 2.2 2.2	1 1 1 1 1

44	Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?. <i>PLoS ONE</i> , <b>2020</b> , 15, e0241634	3.7	О
43	Three monocytic neoplasms in a single patient. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2523-2526	1.9	О
42	Characterization of Subclonal Changes Along Progression in Multiple Myeloma <i>Blood</i> , <b>2012</b> , 120, 2924	- <u>292</u> 4	O
41	Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells. <i>American Journal of Dermatopathology</i> , <b>2020</b> , 42, 360-363	0.9	O
40	Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy. <i>Hemato</i> , <b>2021</b> , 2, 281-30	145.2	O
39	Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2130-2140	1.9	O
38	Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2837-2839	3	
37	MicroRNA in B-Cell Non-Hodgkin's Lymphoma: Diagnostic Markers and Therapeutic Targets <b>2013</b> , 403-4	118	
36	The use of molecular profiling for diagnosis and research in non-Hodgkin's lymphoma. <i>Hematology Reports</i> , <b>2011</b> , 3, e2	0.9	
35	Follicular Lymphoma: Design of a Protein-Based Survival Predictor Using Tissue-Microarrays (TMA) <i>Blood</i> , <b>2004</b> , 104, 2266-2266	2.2	
34	Mantle Cell Lymphoma Genotypes Identified with CGH to BAC Microarrays Define Clinical Subgroups of Disease and Strongly Predict Patient Outcome <i>Blood</i> , <b>2004</b> , 104, 695-695	2.2	
33	Cytogenetic and FISH Study of 92 Patients with Splenic Marginal Zone B-Cell Lymphoma (SMZBCL) <i>Blood</i> , <b>2004</b> , 104, 699-699	2.2	
32	Clinical and Biological Relevance of NF- <b>B</b> Activation in B-CLL <i>Blood</i> , <b>2004</b> , 104, 2792-2792	2.2	
31	Identification of Surrogate Prognostic Markers and Genes Implicated in Immunoglobulin Gene (IgVH) Somatic Hypermutation in Small B-Cell Lymphomas <i>Blood</i> , <b>2005</b> , 106, 1004-1004	2.2	
30	FOXP3 Expression in B and T Cell Lymphomas <i>Blood</i> , <b>2005</b> , 106, 4503-4503	2.2	
29	Transcriptome Classification of B-Cell Non-Hodgkins Lymphoma <i>Blood</i> , <b>2006</b> , 108, 819-819	2.2	
28	Splenic Marginal Zone Lymphoma Shows a Distinct Pattern of DNA Copy Number Aberrations That Correlates with Tumor Characteristics and Predicts Disease Outcome <i>Blood</i> , <b>2006</b> , 108, 2422-2422	2.2	
27	The Expression of T Cell Receptor Signaling Genes Is Associated with Poor Response to IFN-II and/or PUVA in Mycosis Fungoides <i>Blood</i> , <b>2006</b> , 108, 2053-2053	2.2	

26	The BCL6 Oncogene Drives an Epigenomic Program Linking Stem Cells to the Pathogenesis of Human Diffuse Large B Cell Lymphoma in Mice <i>Blood</i> , <b>2007</b> , 110, 3372-3372	2.2
25	Mycosis Fungoide: Immunochemistry Analysis of Lymphoid and Microenvironment Cells by Macrotissue Array <i>Blood</i> , <b>2007</b> , 110, 4400-4400	2.2
24	Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population. <i>Blood</i> , <b>2018</b> , 132, 2938-2938	2.2
23	Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines. <i>Blood</i> , <b>2018</b> , 132, 2851-285	12.2
22	Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 5383-5383	2.2
21	Tumour Suppressor Genes in Hodgkin⊠ Disease <b>1995</b> , 209-222	
20	NF- <b>B</b> Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , <b>2014</b> , 124, 1620-1620	2.2
19	Analysis of the Genomic Heterogeneity in Hodgkin Lymphoma Using Next Generation Sequencing. <i>Blood</i> , <b>2015</b> , 126, 178-178	2.2
18	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , <b>2008</b> , 112, 478-478	2.2
17	Integrative Analysis of MicroRNA and Gene Expression Profiling Contributes to Understand Mantle Cell Lymphoma Pathogenesis <i>Blood</i> , <b>2009</b> , 114, 2936-2936	2.2
16	Molecular Heterogeneity as a Basis for Rational Therapeutics in Chronic Lymphocytic Leukemia <i>Blood</i> , <b>2009</b> , 114, 2348-2348	2.2
15	NIK Is Involved In the Activation of the Classical and Alternative NF <b>-B</b> Pathways In Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 3099-3099	2.2
14	A Novel Pro-Survival Function of Cyclin-D1 Underlies Its Oncogenic Role and Potential as a Therapeutic Target In Mantle Cell Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 769-769	2.2
13	Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples. <i>Blood</i> , <b>2010</b> , 116, 2470-2470	2.2
12	Mirna EXPRESSION SIGNATURES as PROGNOSTIC Markers IN ADVANCED Classical HODGKIN LYMPHOMA. <i>Blood</i> , <b>2010</b> , 116, 4157-4157	2.2
11	PIM Kinases Inhibition, a Rational Strategy in Peripheral T-Cell Lymphomas,. <i>Blood</i> , <b>2011</b> , 118, 3494-349	42.2
10	The NF- <b>B</b> -Inducing Kinase (NIK) Is Involved in Both Classical and Alternative NF- <b>B</b> Activation and Is Necessary for the Survival of T Cell Lymphoma Cells,. <i>Blood</i> , <b>2011</b> , 118, 3665-3665	2.2
9	Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?. <i>Blood</i> , <b>2011</b> , 118, 2638-2638	2.2

8	PI3K Inhibition As a Potential Therapeutic Strategy in Peripheral T-Cell Lymphomas,. <i>Blood</i> , <b>2011</b> , 118, 3493-3493	2.2
7	Clonal Selection in the Ontogeny and Evolution of Splenic Marginal Zone Lymphoma Confirming the Existence of Distinct Molecular Subtypes. <i>Blood</i> , <b>2012</b> , 120, 1556-1556	2.2
6	Mutational Status of Splenic Marginal Zone Lymphoma Revealed by Whole Exome Sequencing <i>Blood</i> , <b>2012</b> , 120, 2698-2698	2.2
5	Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas. <i>Blood</i> , <b>2012</b> , 120, 300-300	2.2
4	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium	2.2
3	Program. <i>Blood</i> , <b>2013</b> , 122, 363-363  An analysis of genetic targets for guiding clinical management of follicular lymphoma. <i>Expert Review of Hematology</i> , <b>2020</b> , 13, 1361-1372	2.8
2	Nodal marginal zone mutational signature. <i>Blood</i> , <b>2016</b> , 128, 1315-6	2.2
1	Search for the cause of anaemia and neutropenia in a patient with well-controlled systemic lupus erythematosus <i>International Journal of Laboratory Hematology</i> , <b>2022</b> ,	2.5